WARNINGS
What is the most important information I should know about REMICADE?
REMICADE may cause serious side effects, including:
1. Risk of infection
REMICADE is a medicine that affects your immune system. REMICADE can lower the ability of your immune system to fight infections.
Serious infections have happened in patients receiving REMICADE. These infections include tuberculosis (TB) and infections caused by viruses, fungi or bacteria that have spread throughout the body. Some patients have died from these infections.
• Your doctor should test you for TB before starting REMICADE.
• Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE.
Before starting REMICADE, tell your doctor if you:
• think you have an infection. You should not start receiving REMICADE if you have any kind of infection.
• are being treated for an infection.
• have signs of an infection, such as a fever, cough, flu-like symptoms.
• have any open cuts or sores on your body.
• get a lot of infections or have infections that keep coming back.
• have diabetes or an immune system problem. People with these conditions have a higher chance for infections.
• have TB, or have been in close contact with someone with TB.
• live or have lived in certain parts of the country (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections (histoplasmosis, coccidioidomycosis, or blastomycosis). These infections may develop or become more severe if you receive REMICADE. If you do not know if you have lived in an area where histoplasmosis, coccidioidomycosis, or blastomycosis is common, ask your doctor.
• have or have had hepatitis B.
• use the medicines KINERET (anakinra), ORENCIA (abatacept), ACTEMRA (tocilizumab), or other medicines called biologics used to treat the same conditions as REMICADE.
After starting REMICADE, if you have an infection, any sign of an infection including a fever, cough, flu-like symptoms, or have open cuts or sores on your body, call your doctor right away. REMICADE can make you more likely to get infections or make any infection that you have worse.
2. Risk of Cancer
• There have been cases of unusual cancers in children and teenage patients using tumor necrosis factor (TNF) blocker medicines.
• For children and adults receiving TNF blocker medicines, including REMICADE, the chances of getting lymphoma or other cancers may increase.
• Some people receiving TNF blockers, including REMICADE, developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. Most of these people were male teenagers or young men. Also, most people were being treated for Crohn’s disease or ulcerative colitis with a TNF blocker and another medicine called azathioprine or 6-mercaptopurine.
• People who have been treated for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis for a long time may be more likely to develop lymphoma. This is especially true for people with very active disease.
• Some people treated with REMICADE have developed certain kinds of skin cancer. If any changes in the appearance of your skin or growths on your skin occur during or after your treatment with REMICADE, tell your doctor.
• Patients with Chronic Obstructive Pulmonary Disease (COPD), a specific type of lung disease, may have an increased risk for getting cancer while being treated with REMICADE. Some women being treated for rheumatoid arthritis with REMICADE have developed cervical cancer. For women receiving REMICADE, including those over 60 years of age, your doctor may recommend that you continue to be regularly screened for cervical cancer.
• Tell your doctor if you have ever had any type of cancer. Discuss with your doctor any need to adjust medicines you may be taking.
See the section SIDE EFFECTS below.
USES
What is REMICADE?
REMICADE is a prescription medicine that is approved for patients with:
• Rheumatoid Arthritis - adults with moderately to severely active rheumatoid arthritis, along with the medicine methotrexate.
• Crohn’s Disease - children 6 years and older and adults with Crohn’s disease who have not responded well to other medicines.
• Ankylosing Spondylitis in adults
• Psoriatic Arthritis in adults
• Plaque Psoriasis - adult patients with plaque psoriasis that is chronic (does not go away), severe, extensive, and/or disabling.
• Ulcerative Colitis - children 6 years and older and adults with moderately to severely active ulcerative colitis who have not responded well to other medicines.
REMICADE blocks the action of a protein in your body called tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is made by your body’s immune system. People with certain diseases have too much TNF-alpha that can cause the immune system to attack normal healthy parts of the body. REMICADE can block the damage caused by too much TNF-alpha. It is not known if REMICADE is safe and effective in children under 6 years of age.
HOW TO USE
How should I receive REMICADE?
• You will be given REMICADE through a needle placed in a vein (IV or intravenous infusion) in your arm.
• Your doctor may decide to give you medicine before starting the REMICADE infusion to prevent or lessen side effects.
• Only a healthcare professional should prepare the medicine and administer it to you.
• REMICADE will be given to you over a period of about 2 hours.
• If you have side effects from REMICADE, the infusion may need to be adjusted or stopped. In addition, your healthcare professional
may decide to treat your symptoms.
• A healthcare professional will monitor you during the REMICADE infusion and for a period of time afterward for side effects. Your
doctor may do certain tests while you are receiving REMICADE to monitor you for side effects and to see how well you respond to the treatment.
• Your doctor will determine the right dose of REMICADE for you and how often you should receive it. Make sure to discuss with your doctor when you will receive infusions and to come in for all your infusions and follow-up appointments.
What are the possible side effects of REMICADE?
REMICADE can cause serious side effects, including:
See “What is the most important information I should know about REMICADE?”
Serious Infections
• Some patients, especially those 65 years and older have had serious infections while receiving REMICADE. These serious infections include TB and infections caused by viruses, fungi, or bacteria that have spread throughout the body or cause infections in certain areas (such as skin). Some patients die from these infections. If you get an infection while receiving treatment with REMICADE your doctor will treat your infection and may need to stop your REMICADE treatment.
• Tell your doctor right away if you have any of the following signs of an infection while receiving or after receiving REMICADE:
° a fever ° have flu-like symptoms
° feel very tired ° warm, red, or painful skin
° have a cough
• Your doctor will examine you for TB and perform a test to see if you have TB. If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with REMICADE and during treatment with REMICADE.
• Even if your TB test is negative, your doctor should carefully monitor you for TB infections while you are receiving REMICADE. Patients who had a negative TB skin test before receiving REMICADE have developed active TB.
• If you are a chronic carrier of the hepatitis B virus, the virus can become active while you are being treated with REMICADE. In some cases, patients have died as a result of hepatitis B virus being reactivated. Your doctor should do a blood test for hepatitis B virus before you start treatment with REMICADE and occasionally while you are being treated. Tell your doctor if you have any of the following symptoms:
° feel unwell ° tiredness (fatigue)
° poor appetite ° fever, skin rash, or joint pain
Other Heart Problems
Some patients have experienced a heart attack (some of which led to death), low blood flow to the heart, or abnormal heart rhythm within 24 hours of beginning their infusion of REMICADE. Symptoms may include chest discomfort or pain, arm pain, stomach pain, shortness of breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea, vomiting, fluttering or pounding in your chest, and/or a fast or a slow heartbeat. Tell your doctor right away if you have any of these symptoms.
Liver Injury
Some patients receiving REMICADE have developed serious liver problems. Tell your doctor if you have:
• jaundice (skin and eyes turning yellow) • fever
• dark brown-colored urine • extreme tiredness (severe fatigue)
• pain on the right side of your stomach area
(right-sided abdominal pain)
Blood Problems
In some patients receiving REMICADE, the body may not make enough of the blood cells that help fight infections or help stop bleeding. Tell your doctor if you:
• have a fever that does not go away • look very pale
• bruise or bleed very easily Nervous System Disorders
Some patients receiving REMICADE have developed problems with their nervous system. Tell your doctor if you have:
• changes in your vision • seizures
• numbness or tingling in any part of your body • weakness in your arms or legs Some patients have experienced a stroke within approximately 24 hours of their infusion with REMICADE. Tell your doctor right away if you have symptoms of a stroke which may include: numbness or weakness of the face, arm or leg, especially on one side of the body; sudden confusion, trouble speaking or understanding; sudden trouble seeing in one or both eyes, sudden trouble walking, dizziness, loss of balance or coordination or a sudden, severe headache.
Allergic Reactions
Some patients have had allergic reactions to REMICADE. Some of these reactions were severe. These reactions can happen while
you are getting your REMICADE treatment or shortly afterward. Your doctor may need to stop or pause your treatment with REMICADE
and may give you medicines to treat the allergic reaction. Signs of an allergic reaction can include:
hives (red, raised, itchy patches of skin) • high or low blood pressure
difficulty breathing • fever
chest pain • chills
Some patients treated with REMICADE have had delayed allergic reactions. The delayed reactions occurred 3 to 12 days after receiving treatment with REMICADE. Tell your doctor right away if you have any of these signs of delayed allergic reaction to REMICADE:
• fever • muscle or joint pain
• rash • swelling of the face and hands
• headache • difficulty swallowing
• sore throat
Lupus-like Syndrome
Some patients have developed symptoms that are like the symptoms of Lupus. If you develop any of the following symptoms, your doctor may decide to stop your treatment with REMICADE.
• chest discomfort or pain that does not go away
• joint pain
• shortness of breath
• rash on the cheeks or arms that gets worse in the sun
Psoriasis
Some people receiving REMICADE had new psoriasis or worsening of psoriasis they already had. Tell your doctor if you develop red scaly patches or raised bumps on the skin that are filled with pus. Your doctor may decide to stop your treatment with REMICADE.
The most common side effects of REMICADE include:
• respiratory infections, such as sinus
• coughing infections and sore throat
• stomach pain
• headache
Infusion reactions can happen up to 2 hours after your infusion of REMICADE. Symptoms of infusion reactions may include:
• fever
• shortness of breath
• chills
• rash
• chest pain
• itching
• low blood pressure or high blood pressure
Children who received REMICADE in studies for Crohn’s disease showed some differences in side effects compared with adults who received REMICADE for Crohn’s disease. The side effects that happened more in children were: anemia (low red blood cells), leukopenia (low white blood cells), flushing (redness or blushing), viral infections, neutropenia (low neutrophils, the white blood cells that fight infection), bone fracture, bacterial infection and allergic reactions of the breathing tract. Among patients who received REMICADE for ulcerative colitis in clinical studies, more children had infections as compared with adults.
Tell your doctor about any side effect that bothers you or does not go away.
These are not all of the side effects with REMICADE. Ask your doctor or pharmacist for more information.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088
General information about REMICADE
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your doctor or pharmacist for information about REMICADE that is written for health professionals.
What are the ingredients in REMICADE?
The active ingredient is Infliximab.
The inactive ingredients in REMICADE include: dibasic sodium phosphate dihydrate, monobasic sodium phosphate monohydrate, polysorbate 80, and sucrose. No preservatives are present.
OVERDOSE
Please call your healthcare provider for more information.
MISSED DOSE
Please call your healthcare provider for more information.
STORAGE
Store unopened REMICADE® vials in a refrigerator at 2 -degrees C to 8-degrees C (36-degrees F to 46-degrees F). If needed, unopened REMICADE vials may be stored at room temperatures up to a maximum of 30 ºC (86-degrees F) for a single period of up to 6 months but not exceeding the original expiration date. The new expiration date must be written in the space provided on the carton. Once removed from the refrigerator, REMICADE cannot be returned to the refrigerator.
NOTES
Medication Guide: revision date 02/2025
Prescribing Information: revision date 02/2025
1. Other Biological Products
The combination of REMICADE with other biological products used to treat
the same conditions as REMICADE is not recommended [see the sections WARNINGS and PRECAUTIONS above].
An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of REMICADE and anakinra or abatacept is not recommended [see the sections WARNINGS and PRECAUTIONS above]. The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including REMICADE, should be avoided because of the possibility of increased immunosuppression and increased risk of infection.
2. Methotrexate and Other Concomitant Medications
Specific drug interaction studies, including interactions with methotrexate (MTX), have not been conducted. The majority of patients in RA or CD clinical studies received one or more concomitant medications. In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics. Concomitant CD medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates. In PsA clinical trials, concomitant medications included MTX in approximately half of the patients as well as NSAIDs, folic acid and corticosteroids. Concomitant MTX use may decrease the incidence of anti-infliximab antibody production and increase infliximab concentrations.
3. Immunosuppressants
Patients with CD who received immunosuppressants tended to experience fewer infusion reactions compared to patients on no immunosuppressants. Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of CD including corticosteroids, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.
4. Cytochrome P450 Substrates
The formation of CYP450 enzymes may be suppressed by increased levels of cytokines (e.g., TNFα, IL-1, IL-6, IL-10, IFN) during chronic inflammation. Therefore, it is expected that for a molecule that antagonizes cytokine activity, such as infliximab, the formation of CYP450 enzymes could be normalized. Upon initiation or discontinuation of REMICADE in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed.
5. Live Vaccines/Therapeutic Infectious Agents
It is recommended that live vaccines not be given concurrently with REMICADE. It is also recommended that live vaccines not be given to infants after in utero exposure to infliximab for at least 6 months following birth [see the sections WARNINGS and PRECAUTIONS above].
It is recommended that therapeutic infectious agents not be given concurrently with REMICADE [see the sections WARNINGS and PRECAUTIONS above].
Who should not receive REMICADE? You should not receive REMICADE if you have: • heart failure, unless your doctor has examined you and decided that you are able to receive REMICADE. Talk to your doctor about your heart failure. • had an allergic reaction to REMICADE, or any of the other ingredients in REMICADE. See the end of this Medication Guide for a complete list of ingredients in REMICADE.
What should I tell my doctor before starting treatment with REMICADE?
Your doctor will assess your health before each treatment.
Tell your doctor about all of your medical conditions, including if you:
• have an infection (see “What is the most important information I should know about REMICADE?”).
• have other liver problems including liver failure.
• have heart failure or other heart conditions. If you have heart failure, it may get worse while you receive REMICADE.
• have or have had any type of cancer.
• have had phototherapy (treatment with ultraviolet light or sunlight along with a medicine to make your skin sensitive to light) for psoriasis. You may have a higher chance of getting skin cancer while receiving REMICADE.
• have COPD, a specific type of lung disease. Patients with COPD may have an increased risk of getting cancer while receiving REMICADE.
• have or have had a condition that affects your nervous system such as:
° multiple sclerosis, or Guillain-Barré syndrome, or
° if you experience any numbness or tingling, or
° if you have had a seizure.
• have recently received or are scheduled to receive a vaccine. Adults and children receiving REMICADE should not receive live vaccines (for example, the Bacille Calmette-Guérin [BCG] vaccine) or treatment with a weakened bacteria (such as BCG for bladder cancer). Adults and children should have all of their vaccines brought up to date before starting treatment with REMICADE.
• are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed. You and your doctor should decide if you should receive REMICADE while you are pregnant or breastfeeding. If you have a baby and you were receiving REMICADE during your pregnancy, it is important to tell your baby’s doctor and other health-care professionals about your REMICADE use so they can decide when your baby should receive any vaccine. Certain vaccinations can cause infections.
If you received REMICADE while you were pregnant, your baby may be at higher risk for getting an infection. If your baby receives a live vaccine within 6 months after birth, your baby may develop infections with serious complications that can lead to death. This includes live vaccines such as the BCG, rotavirus, or any other live vaccines. For other types of vaccines, talk with your doctor.
What should I avoid while receiving REMICADE?
Do not take REMICADE together with medicines such as KINERET (anakinra), ORENCIA (abatacept), ACTEMRA (tocilizumab), or other medicines called biologics that are used to treat the same conditions as REMICADE.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. These include any other medicines to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or psoriasis.
Know the medicines you take. Keep a list of your medicines and show them to your doctor and pharmacist when you get a new medicine.
